Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-06-09 5:02 pm Purchase | 2026-06-08 | 13G | DESIGN THERAPEUTICS INC DSGN | Point72 Asset Management, L.P. | 3,197,764 5.100% | 475,010 (+17.45%) | Filing History |
| 2026-05-15 4:26 pm Sale | 2026-03-31 | 13G | DESIGN THERAPEUTICS INC DSGN | Point72 Asset Management, L.P. | 2,722,754 4.400% | -2,649,250 (-49.32%) | Filing History |
| 2026-03-11 9:28 pm Purchase | 2026-03-09 | 13D | DESIGN THERAPEUTICS INC DSGN | SR One Capital Fund I Aggregator, LP | 6,607,892 10.700% | 57,666 (+0.88%) | Filing History |
| 2026-02-17 4:27 pm Purchase | 2025-12-31 | 13G | DESIGN THERAPEUTICS INC DSGN | Point72 Asset Management, L.P. | 5,372,004 9.400% | 2,429,285 (+82.55%) | Filing History |
| 2025-11-18 5:57 pm Sale | 2025-11-14 | 13D | DESIGN THERAPEUTICS INC DSGN | Logos Global Management LP | 2,515,000 4.400% | -740,000 (-22.73%) | Filing History |
| 2025-11-12 5:10 pm Sale | 2025-11-07 | 13D | DESIGN THERAPEUTICS INC DSGN | Logos Global Management LP | 3,255,000 5.700% | -977,627 (-23.10%) | Filing History |
| 2025-08-28 4:05 pm Purchase | 2025-08-27 | 13G | DESIGN THERAPEUTICS INC DSGN | Point72 Asset Management, L.P. | 2,942,719 5.200% | 2,942,719 (New Position) | Filing History |
| 2025-02-07 4:16 pm Unchanged | 2024-12-31 | 13G | DESIGN THERAPEUTICS INC DSGN | Star Irrevocable Trust #1 dated April 22, 2019 | 3,834,355 6.900% | 0 (Unchanged) | Filing History |
| 2025-02-07 4:15 pm Unchanged | 2024-12-31 | 13G | DESIGN THERAPEUTICS INC DSGN | Light Irrevocable Trust #1 dated April 22, 2019 | 3,834,355 6.900% | 0 (Unchanged) | Filing History |
| 2024-08-13 6:53 pm Purchase | 2024-08-09 | 13D | DESIGN THERAPEUTICS INC DSGN | Logos Global Management LP | 4,232,627 7.500% | 1,420,126 (+50.49%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | DESIGN THERAPEUTICS INC DSGN | Citadel Advisors LLC | 1,834,854 3.300% | -1,036,413 (-36.10%) | Filing History |
| 2024-02-14 3:01 pm Sale | 2023-12-31 | 13G | CONSTELLATION PHARMACEUTICALS CNST | Cormorant Asset Management, LP | 0 0.000% | -5,150,000 (Position Closed) | Filing History |
| 2024-01-23 10:34 am Sale | 2023-12-31 | 13G | DESIGN THERAPEUTICS INC DSGN | STATE STREET CORPORATION STT | 695,224 1.240% | -2,342,236 (-77.11%) | Filing History |
| 2023-11-14 5:00 pm Sale | 2023-11-14 | 13G | DESIGN THERAPEUTICS INC DSGN | RA Capital Management, L.P. | 0 0.000% | -2,971,231 (Position Closed) | Filing History |
| 2023-09-07 09:38 am Sale | 2023-08-31 | 13G | DESIGN THERAPEUTICS INC DSGN | BlackRock Inc. BLK | 2,394,544 4.300% | -1,113,480 (-31.74%) | Filing History |
| 2023-04-03 4:55 pm Purchase | 2023-03-23 | 13G | DESIGN THERAPEUTICS INC DSGN | Citadel Advisors LLC | 2,871,267 5.100% | 203,037 (+7.61%) | Filing History |
| 2023-02-14 3:14 pm Sale | 2022-12-31 | 13G | CONSTELLATION PHARMACEUTICALS CNST | Cormorant Asset Management, LP | 5,150,000 9.210% | -290,451 (-5.34%) | Filing History |
| 2023-02-14 08:14 am Sale | 2022-12-31 | 13G | DESIGN THERAPEUTICS INC DSGN | Citadel Advisors LLC | 2,668,230 4.800% | -40,017 (-1.48%) | Filing History |
| 2023-02-08 1:03 pm Purchase | 2022-12-31 | 13G | DESIGN THERAPEUTICS INC DSGN | STATE STREET CORPORATION STT | 3,037,460 5.430% | 3,037,460 (New Position) | Filing History |
| 2023-02-03 12:10 pm Purchase | 2022-12-31 | 13G | DESIGN THERAPEUTICS INC DSGN | BlackRock Inc. BLK | 3,508,024 6.300% | 3,508,024 (New Position) | Filing History |